S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

$4.70
-0.14 (-2.89%)
(As of 03/27/2024 ET)
Today's Range
$4.70
$4.70
50-Day Range
$4.64
$6.99
52-Week Range
$3.57
$14.70
Volume
1,496 shs
Average Volume
1,912 shs
Market Capitalization
$22.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PYPD stock logo

About PolyPid Stock (NASDAQ:PYPD)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD Stock Price History

PYPD Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
PolyPid Ltd. (PYPD)
PolyPid's Earnings: A Preview
See More Headlines
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/27/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-23,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.27) per share

Miscellaneous

Free Float
1,245,000
Market Cap
$22.56 million
Optionable
Optionable
Beta
1.43
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Dikla Czaczkes Akselbrad (Age 51)
    CEO & Director
    Comp: $422.33k
  • Ms. Dalit Hazan (Age 53)
    Executive Vice President of R&D and Clinical & Regulatory Affairs
    Comp: $312.25k
  • Mr. Ori Warshavsky (Age 46)
    Chief Operating Officer - US
    Comp: $335.52k
  • Mr. Jonny Missulawin (Age 37)
    Chief Financial Officer
  • Ms. Maria Rubin
    Vice President of Operations
  • Mr. Tal Vilnai
    General Counsel & Corporate Secretary
  • Ms. Rivi Lev-ari
    Vice President of Human Resource
  • Dr. Jean-Marc Hagai Pharm.D.
    Chief Commercial Officer

PYPD Stock Analysis - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings
or view top-rated stocks.

How have PYPD shares performed in 2024?

PolyPid's stock was trading at $3.80 at the beginning of 2024. Since then, PYPD shares have increased by 23.7% and is now trading at $4.70.
View the best growth stocks for 2024 here
.

When is PolyPid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PYPD earnings forecast
.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($3.97) EPS for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80.

When did PolyPid's stock split?

PolyPid's stock reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets served as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Who are PolyPid's major shareholders?

PolyPid's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYPD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners